[
    {
        "text": "Thanks to Linode Cloud Computing for supporting\nthis episode of SciShow.",
        "start": 0.19,
        "duration": 3.15
    },
    {
        "text": "Head to linode.com/scishow to learn more and\nget a $100 60-day credit",
        "start": 3.34,
        "duration": 4.53
    },
    {
        "text": "on a new Linode account.",
        "start": 7.87,
        "duration": 1.389
    },
    {
        "text": "[♪ INTRO]",
        "start": 9.259,
        "duration": 2.151
    },
    {
        "text": "There’s a big new Alzheimer’s treatment\non the block.",
        "start": 11.41,
        "duration": 3.829
    },
    {
        "text": "It’s the first drug approved by the FDA\nhere in the US that claims to stop",
        "start": 15.239,
        "duration": 3.811
    },
    {
        "text": "Alzheimer’s at the source, by removing the\nplaques that cause disease.",
        "start": 19.05,
        "duration": 4.31
    },
    {
        "text": "This new drug, aducanumab, is the first of\nits kind.",
        "start": 23.36,
        "duration": 3.34
    },
    {
        "text": "It’s designed to stick to and help clear\nthe amyloid plaques in the brain",
        "start": 26.7,
        "duration": 4.18
    },
    {
        "text": "long thought to cause the symptoms of Alzheimer’s\ndisease.",
        "start": 30.88,
        "duration": 2.569
    },
    {
        "text": "But there’s a problem.",
        "start": 33.449,
        "duration": 1.68
    },
    {
        "text": "The biomarkers of a disease, like amyloid\nplaques,",
        "start": 35.129,
        "duration": 2.901
    },
    {
        "text": "are meant to be objective measures of that\ndisease.",
        "start": 38.03,
        "duration": 3.279
    },
    {
        "text": "And they seem like they should go hand in\nhand with its clinical symptoms.",
        "start": 41.309,
        "duration": 4.061
    },
    {
        "text": "But they don’t always.",
        "start": 45.37,
        "duration": 1.579
    },
    {
        "text": "And understanding that might make a big difference\nfor how we approach",
        "start": 46.949,
        "duration": 2.991
    },
    {
        "text": "Alzheimer’s treatments going forward.",
        "start": 49.94,
        "duration": 1.899
    },
    {
        "text": "People with Alzheimer’s disease have buildups\nof protein in their brains,",
        "start": 51.839,
        "duration": 3.57
    },
    {
        "text": "consisting of two main types:",
        "start": 55.409,
        "duration": 1.95
    },
    {
        "text": "tangles of tau within cells, and of amyloid-beta\noutside of cells.",
        "start": 57.359,
        "duration": 4.171
    },
    {
        "text": "That amyloid-beta accumulates into plaques.",
        "start": 61.53,
        "duration": 2.9
    },
    {
        "text": "Aducanumab was designed to lock onto amyloid\nplaques",
        "start": 64.43,
        "duration": 2.76
    },
    {
        "text": "and help the immune system identify and remove\nthem.",
        "start": 67.19,
        "duration": 2.61
    },
    {
        "text": "This was all in line with the dominant theory\nof what causes Alzheimer’s disease:",
        "start": 69.8,
        "duration": 3.91
    },
    {
        "text": "the amyloid hypothesis.",
        "start": 73.71,
        "duration": 1.34
    },
    {
        "text": "Basically, scientists saw those plaques accumulating\nin those with Alzheimer’s",
        "start": 75.05,
        "duration": 4.11
    },
    {
        "text": "and concluded that that’s probably…",
        "start": 79.16,
        "duration": 2.26
    },
    {
        "text": "not what should be happening.",
        "start": 81.42,
        "duration": 1.11
    },
    {
        "text": "In the 80s and 90s, scientists discovered\nthat amyloid-beta is a chopped down",
        "start": 82.53,
        "duration": 4.67
    },
    {
        "text": "version of a larger protein, known as amyloid\nprecursor protein or APP.",
        "start": 87.2,
        "duration": 4.87
    },
    {
        "text": "And later, they came across the enzymes that\ndo the chopping:",
        "start": 92.07,
        "duration": 4.07
    },
    {
        "text": "β-secretase and γ-secretase.",
        "start": 96.14,
        "duration": 1.25
    },
    {
        "text": "But the amyloid hypothesis really got legs\nwhen scientists discovered that genetics",
        "start": 97.39,
        "duration": 4.79
    },
    {
        "text": "relating to these enzymes played a big role\nin one type of inheritable Alzheimer’s.",
        "start": 102.18,
        "duration": 4.62
    },
    {
        "text": "Alzheimer’s most often develops in people\nwith no family history of the disease.",
        "start": 106.8,
        "duration": 3.92
    },
    {
        "text": "But some cases have a strong genetic component,",
        "start": 110.72,
        "duration": 2.81
    },
    {
        "text": "and identifying those genes should help us\nunderstand the causes of Alzheimer’s.",
        "start": 113.53,
        "duration": 4.27
    },
    {
        "text": "In the 90s, researchers pinpointed PSEN1 and\nPSEN2.",
        "start": 117.8,
        "duration": 4.65
    },
    {
        "text": "These genes affect where the secretases cut\nAPP,",
        "start": 122.45,
        "duration": 3.22
    },
    {
        "text": "which determines the length of the amyloid-beta\nfragments.",
        "start": 125.67,
        "duration": 2.2
    },
    {
        "text": "That finding was super important, because\nlonger lengths of amyloid-beta",
        "start": 127.87,
        "duration": 4.32
    },
    {
        "text": "clump together a lot more easily.",
        "start": 132.19,
        "duration": 1.94
    },
    {
        "text": "And the easier they clump, the more readily\namyloid plaques form.",
        "start": 134.13,
        "duration": 3.98
    },
    {
        "text": "Scientists were able to see plaques forming\nin people",
        "start": 138.11,
        "duration": 1.81
    },
    {
        "text": "with variants of PSEN1 and 2 that favor long\namyloid-beta.",
        "start": 139.92,
        "duration": 4.81
    },
    {
        "text": "Those same gene variants were seen in people\nwith familial Alzheimer’s.",
        "start": 144.73,
        "duration": 2.96
    },
    {
        "text": "Because of that, researchers felt like there\nwas a really good case",
        "start": 147.69,
        "duration": 3.01
    },
    {
        "text": "for amyloid being the culprit in causing Alzheimer’s.",
        "start": 150.7,
        "duration": 3.17
    },
    {
        "text": "If that hypothesis is correct, then if we\ncould take those plaques out,",
        "start": 153.87,
        "duration": 4.03
    },
    {
        "text": "we should have a cure, right?",
        "start": 157.9,
        "duration": 1.67
    },
    {
        "text": "Well, unfortunately…",
        "start": 159.57,
        "duration": 1.0
    },
    {
        "text": "the results of our massive effort to cure\nAlzheimer’s",
        "start": 160.57,
        "duration": 2.639
    },
    {
        "text": "by treating amyloid have fallen very flat.",
        "start": 163.209,
        "duration": 2.791
    },
    {
        "text": "One meta-analysis, published in 2021, pooled\ndata from",
        "start": 166.0,
        "duration": 3.62
    },
    {
        "text": "14 randomized controlled trials to look for\nevidence that drugs",
        "start": 169.62,
        "duration": 3.56
    },
    {
        "text": "which reduced amyloid plaques also improved\ncognition in participants.",
        "start": 173.18,
        "duration": 4.67
    },
    {
        "text": "Amyloid plaques are a key biomarker of Alzheimer’s.",
        "start": 177.85,
        "duration": 2.469
    },
    {
        "text": "That can be a broad term, but in this case,\nit’s basically something we can measure",
        "start": 180.319,
        "duration": 4.061
    },
    {
        "text": "objectively that’s associated with the disease,",
        "start": 184.38,
        "duration": 3.06
    },
    {
        "text": "which is often very useful in clinical trials.",
        "start": 187.44,
        "duration": 2.295
    },
    {
        "text": "But!",
        "start": 189.735,
        "duration": 0.762
    },
    {
        "text": "If you clear away a biomarker, but it doesn’t\nactually help patients,",
        "start": 190.497,
        "duration": 4.203
    },
    {
        "text": "you’re not curing the disease at all.",
        "start": 194.7,
        "duration": 2.15
    },
    {
        "text": "Which is why a drug that affects a biomarker\nalso needs to affect",
        "start": 196.85,
        "duration": 3.6
    },
    {
        "text": "the clinical signs of the disease,",
        "start": 200.45,
        "duration": 2.09
    },
    {
        "text": "and improve how people actually feel or decrease\ntheir need for medical care.",
        "start": 202.54,
        "duration": 4.32
    },
    {
        "text": "In medical parlance, it needs to improve patient\noutcomes.",
        "start": 206.86,
        "duration": 3.489
    },
    {
        "text": "Taken together, the data from all trials showed\nthat those given",
        "start": 210.349,
        "duration": 3.491
    },
    {
        "text": "the amyloid-targeting treatments didn’t\nexperience any significant improvements",
        "start": 213.84,
        "duration": 4.79
    },
    {
        "text": "in their cognitive symptoms.",
        "start": 218.63,
        "duration": 1.84
    },
    {
        "text": "Which is part of what makes the approval of\na new drug",
        "start": 220.47,
        "duration": 2.5
    },
    {
        "text": "targeting just plaques kind of bizarre.",
        "start": 222.97,
        "duration": 2.65
    },
    {
        "text": "If there’s evidence targeting amyloid in\nvarious ways doesn’t seem to make a",
        "start": 225.62,
        "duration": 3.4
    },
    {
        "text": "difference, why are we licensing a drug that\ndoes just that as a treatment?",
        "start": 229.02,
        "duration": 4.5
    },
    {
        "text": "This is the part of the episode where I should\nbe able to pull out the stats",
        "start": 233.52,
        "duration": 2.83
    },
    {
        "text": "from aducanumab’s clinical trial and argue",
        "start": 236.35,
        "duration": 2.56
    },
    {
        "text": "that it had some effect on cognitive symptoms.",
        "start": 238.91,
        "duration": 2.37
    },
    {
        "text": "But in fact, I’m going to do the exact opposite!",
        "start": 241.28,
        "duration": 2.41
    },
    {
        "text": "The team conducting these trials didn’t\npost any data",
        "start": 243.69,
        "duration": 2.89
    },
    {
        "text": "suggesting that it improved cognitive symptoms\nin Alzheimer’s patients.",
        "start": 246.58,
        "duration": 3.53
    },
    {
        "text": "The phase three trials for aducanumab were\nactually stopped prematurely",
        "start": 250.11,
        "duration": 3.709
    },
    {
        "text": "in March 2019.",
        "start": 253.819,
        "duration": 1.411
    },
    {
        "text": "That’s the biggest and last phase of human\ntrials",
        "start": 255.23,
        "duration": 2.819
    },
    {
        "text": "before a drug is submitted for approval.",
        "start": 258.049,
        "duration": 1.97
    },
    {
        "text": "The trials were stopped because data indicated\nthat the drug",
        "start": 260.019,
        "duration": 2.661
    },
    {
        "text": "wasn’t going to meet its goals of improving\nAlzheimer’s symptoms.",
        "start": 262.68,
        "duration": 3.37
    },
    {
        "text": "At the time, one trial was trending positive,\njust not enough.",
        "start": 266.05,
        "duration": 3.67
    },
    {
        "text": "The other showed no statistical benefits.",
        "start": 269.72,
        "duration": 1.84
    },
    {
        "text": "They did, however, demonstrate a reduction\nin what was considered",
        "start": 271.56,
        "duration": 2.91
    },
    {
        "text": "a key biomarker: the amount of amyloid plaque.",
        "start": 274.47,
        "duration": 3.05
    },
    {
        "text": "Just not clinically meaningful endpoints,\nlike symptom reduction.",
        "start": 277.52,
        "duration": 2.77
    },
    {
        "text": "And, that’s where the phase three research\nended.",
        "start": 280.29,
        "duration": 3.36
    },
    {
        "text": "On a cliff-hanger.",
        "start": 283.65,
        "duration": 1.0
    },
    {
        "text": "Despite this, in 2021 the FDA approved aducanumab\nanyway,",
        "start": 284.65,
        "duration": 4.02
    },
    {
        "text": "via its Accelerated Approval Pathway.",
        "start": 288.67,
        "duration": 2.19
    },
    {
        "text": "This means a license was granted based on\na drug’s effect on biomarkers,",
        "start": 290.86,
        "duration": 3.83
    },
    {
        "text": "rather than actual improvements in symptoms\nof cognitive decline.",
        "start": 294.69,
        "duration": 3.29
    },
    {
        "text": "We won’t get into it too much, but this\napproval was decidedly controversial.",
        "start": 297.98,
        "duration": 4.27
    },
    {
        "text": "The drug has failed to get approval in Europe\ndue to the lack of evidence",
        "start": 302.25,
        "duration": 2.98
    },
    {
        "text": "for its effectiveness, as well as some potential\nto cause swelling",
        "start": 305.23,
        "duration": 3.33
    },
    {
        "text": "and bleeding in the brain.",
        "start": 308.56,
        "duration": 1.78
    },
    {
        "text": "Understandably, some patients, families,",
        "start": 310.34,
        "duration": 1.81
    },
    {
        "text": "and doctors are still willing to give aducanumab\na shot.",
        "start": 312.15,
        "duration": 3.16
    },
    {
        "text": "Potential treatments for Alzheimer’s have\nso far been rare,",
        "start": 315.31,
        "duration": 2.95
    },
    {
        "text": "and for some, the possibility of hope is better\nthan nothing.",
        "start": 318.26,
        "duration": 3.33
    },
    {
        "text": "For those who have relatives suffering from\nirreversible cognitive decline,",
        "start": 321.59,
        "duration": 3.55
    },
    {
        "text": "or face the prospect of it themselves in the\nnear future,",
        "start": 325.14,
        "duration": 3.43
    },
    {
        "text": "using a drug that might work can seem like\nthe obvious choice.",
        "start": 328.57,
        "duration": 3.29
    },
    {
        "text": "Among experts, there are mixed opinions -- though\na lot of them are pretty spicy.",
        "start": 331.86,
        "duration": 3.97
    },
    {
        "text": "Some people think it could invigorate research\ninto Alzheimer’s,",
        "start": 335.83,
        "duration": 2.91
    },
    {
        "text": "whereas others think it could set it back\ndecades.",
        "start": 338.74,
        "duration": 2.709
    },
    {
        "text": "Like it or not, aducanumab is now heading\ntoward what researchers",
        "start": 341.449,
        "duration": 3.061
    },
    {
        "text": "are referring to as a phase four study:",
        "start": 344.51,
        "duration": 3.01
    },
    {
        "text": "real world observation of effects on disease\nprogression and cognition.",
        "start": 347.52,
        "duration": 4.03
    },
    {
        "text": "We won’t know the outcome of this for several\nyears.",
        "start": 351.55,
        "duration": 2.74
    },
    {
        "text": "And even if it fails this phase four trial,\nthere’s a possibility that it might still",
        "start": 354.29,
        "duration": 3.58
    },
    {
        "text": "prove useful if given to younger people who\nare at risk",
        "start": 357.87,
        "duration": 2.81
    },
    {
        "text": "of developing Alzheimer’s later down the\nroad.",
        "start": 360.68,
        "duration": 2.65
    },
    {
        "text": "See, there’s actually a lot of evidence\nthat plaques alone",
        "start": 363.33,
        "duration": 2.23
    },
    {
        "text": "aren’t responsible for the kind of cognitive\ndecline we see in this type of dementia.",
        "start": 365.56,
        "duration": 4.14
    },
    {
        "text": "One of the main pieces of evidence we have\nfor this is the fact that there are",
        "start": 369.7,
        "duration": 3.04
    },
    {
        "text": "plenty of people with amyloid plaques that\nshow no signs of dementia at all.",
        "start": 372.74,
        "duration": 4.12
    },
    {
        "text": "In fact, some scientists have suggested that\nthe prevalence of amyloid plaques",
        "start": 376.86,
        "duration": 4.45
    },
    {
        "text": "could be just as high in those without Alzheimer’s\nas those with it.",
        "start": 381.31,
        "duration": 3.96
    },
    {
        "text": "The amount of plaque also doesn’t correlate\nstrongly with Alzheimer’s severity.",
        "start": 385.27,
        "duration": 3.11
    },
    {
        "text": "However, there’s a difference in when different\npathological features",
        "start": 388.38,
        "duration": 3.02
    },
    {
        "text": "arise in the brain.",
        "start": 391.4,
        "duration": 1.41
    },
    {
        "text": "Amyloid plaques appear first, about 10-20\nyears before cognitive symptoms start.",
        "start": 392.81,
        "duration": 4.0
    },
    {
        "text": "So clinical trials looking at the timing of\nstarting therapy are already underway",
        "start": 396.81,
        "duration": 4.21
    },
    {
        "text": "with different amyloid-clearing drugs.",
        "start": 401.02,
        "duration": 1.86
    },
    {
        "text": "But it’s going to be a hot minute…",
        "start": 402.88,
        "duration": 1.67
    },
    {
        "text": "or rather, a hot few decades, before we can\ntake a look at results for studies like that.",
        "start": 404.55,
        "duration": 4.6
    },
    {
        "text": "If aducanumab fails on all fronts at stopping\ncognitive decline, it could be the final",
        "start": 409.15,
        "duration": 4.47
    },
    {
        "text": "nail in the coffin of the Amyloid Hypothesis\nthat dominated the field for many years.",
        "start": 413.62,
        "duration": 5.35
    },
    {
        "text": "We tried every which way to clear plaques,\nand even succeeded.",
        "start": 418.97,
        "duration": 3.169
    },
    {
        "text": "But if that doesn’t affect the clinical\nmanifestation of the disease,",
        "start": 422.139,
        "duration": 3.25
    },
    {
        "text": "that means we’re missing something about\nwhat causes it.",
        "start": 425.389,
        "duration": 2.781
    },
    {
        "text": "But, that doesn’t mean scientists are out\nof options.",
        "start": 428.17,
        "duration": 2.98
    },
    {
        "text": "Right now, researchers are actively looking\nat a few other potential targets.",
        "start": 431.15,
        "duration": 3.56
    },
    {
        "text": "For starters, how about that other protein\ntangle I mentioned earlier: tau.",
        "start": 434.71,
        "duration": 4.44
    },
    {
        "text": "Treatments targeting tau also have a whole\nlot of potential.",
        "start": 439.15,
        "duration": 2.6
    },
    {
        "text": "In a healthy brain, tau is vital for maintaining\nthe internal structure of neurons.",
        "start": 441.75,
        "duration": 4.28
    },
    {
        "text": "But in Alzheimer’s, an abnormal form of\ntau builds up into tangles inside neurons,",
        "start": 446.03,
        "duration": 5.27
    },
    {
        "text": "and causes their internal skeleton structure\nto fall apart.",
        "start": 451.3,
        "duration": 3.589
    },
    {
        "text": "Those neurons then stop working as intended,",
        "start": 454.889,
        "duration": 2.121
    },
    {
        "text": "leading to a general decline in function of\nareas with a lot of tau build up.",
        "start": 457.01,
        "duration": 4.12
    },
    {
        "text": "Now this probably isn’t going to be a case\nof pointing a finger at tau",
        "start": 461.13,
        "duration": 3.16
    },
    {
        "text": "instead of amyloid-beta and being all ‘ah\nha, it was you all along!’.",
        "start": 464.29,
        "duration": 4.92
    },
    {
        "text": "Clinical research is usually more complex\nthan an Agatha Christie novel.",
        "start": 469.21,
        "duration": 3.26
    },
    {
        "text": "What actually seems to be going on is a complex\nrelationship between tau,",
        "start": 472.47,
        "duration": 3.48
    },
    {
        "text": "amyloid-beta, and other factors, and that\nrelationship evolves",
        "start": 475.95,
        "duration": 3.77
    },
    {
        "text": "over the course of the disease.",
        "start": 479.72,
        "duration": 1.46
    },
    {
        "text": "Tau starts out accumulating and replicating\nitself in areas related to memory,",
        "start": 481.18,
        "duration": 4.13
    },
    {
        "text": "namely the entorhinal cortex and hippocampus.",
        "start": 485.31,
        "duration": 2.74
    },
    {
        "text": "And as amyloid continues to accumulate, things\nseem to reach a tipping point,",
        "start": 488.05,
        "duration": 3.989
    },
    {
        "text": "which results in the abnormal tau starting\nto spread throughout the brain,",
        "start": 492.039,
        "duration": 3.991
    },
    {
        "text": "hopping from cell to cell.",
        "start": 496.03,
        "duration": 1.289
    },
    {
        "text": "How exactly it does this, we’re not sure,",
        "start": 497.319,
        "duration": 2.111
    },
    {
        "text": "but some evidence points to tau ‘seeds’\ncrossing synapses.",
        "start": 499.43,
        "duration": 3.67
    },
    {
        "text": "And as it spreads and grows and replicates,",
        "start": 503.1,
        "duration": 2.43
    },
    {
        "text": "more and more neurons become damaged, driving\ncognitive decline.",
        "start": 505.53,
        "duration": 3.729
    },
    {
        "text": "Recent research has shown that in the mid-to-late\nstages of Alzheimer’s,",
        "start": 509.259,
        "duration": 3.33
    },
    {
        "text": "tau replication rather than spread seems to\ndrive neurodegeneration onwards,",
        "start": 512.589,
        "duration": 5.031
    },
    {
        "text": "and therefore cognitive decline.",
        "start": 517.62,
        "duration": 1.659
    },
    {
        "text": "This gives one potential opening for a treatment.",
        "start": 519.279,
        "duration": 2.771
    },
    {
        "text": "What if we could design a drug that stopped\ntau replication, for example?",
        "start": 522.05,
        "duration": 3.83
    },
    {
        "text": "Researchers are already exploring a lot of\noptions,",
        "start": 525.88,
        "duration": 1.88
    },
    {
        "text": "like therapies that stop tau from hopping\nfrom cell to cell,",
        "start": 527.76,
        "duration": 3.44
    },
    {
        "text": "clear tau tangles, or stop tau from becoming\nabnormal in the first place.",
        "start": 531.2,
        "duration": 3.99
    },
    {
        "text": "We have a lot of research on tau already,\nbut the trouble is, much of that previous",
        "start": 535.19,
        "duration": 4.04
    },
    {
        "text": "research thought of tau as its own separate\nentity when it comes to Alzheimer’s.",
        "start": 539.23,
        "duration": 4.52
    },
    {
        "text": "But now, evidence is mounting that it has\nmore of a synergistic relationship",
        "start": 543.75,
        "duration": 3.66
    },
    {
        "text": "with amyloid-beta than being a lone ranger.",
        "start": 547.41,
        "duration": 2.61
    },
    {
        "text": "Not only does this give us a clue as to why\namyloid-only approaches are falling flat,",
        "start": 550.02,
        "duration": 4.21
    },
    {
        "text": "but it may mean scientists have to reassess\nprevious tau research",
        "start": 554.23,
        "duration": 3.59
    },
    {
        "text": "through this lens too.",
        "start": 557.82,
        "duration": 1.26
    },
    {
        "text": "It’s not just tau that scientists are homing\nin on, though.",
        "start": 559.08,
        "duration": 2.58
    },
    {
        "text": "Another popular avenue for research is the\nrole inflammation might play.",
        "start": 561.66,
        "duration": 3.6
    },
    {
        "text": "That is, we’re beginning to understand that\nthe activity of the brain’s immune cells",
        "start": 565.26,
        "duration": 4.11
    },
    {
        "text": "may be a third key feature of Alzheimer’s.",
        "start": 569.37,
        "duration": 2.46
    },
    {
        "text": "When pathogens or amyloid plaques build up,",
        "start": 571.83,
        "duration": 2.59
    },
    {
        "text": "these immune cells, called glial cells, try\ntheir best to clear them out.",
        "start": 574.42,
        "duration": 3.57
    },
    {
        "text": "In the process, they can set off inflammation\nin the brain.",
        "start": 577.99,
        "duration": 3.13
    },
    {
        "text": "When those glial cells go into overdrive in\npeople with Alzheimer’s,",
        "start": 581.12,
        "duration": 3.45
    },
    {
        "text": "their inflammatory output seems to kill off\nneurons.",
        "start": 584.57,
        "duration": 2.68
    },
    {
        "text": "It also seems like this inflammation exacerbates\nboth amyloid and tau build up.",
        "start": 587.25,
        "duration": 4.43
    },
    {
        "text": "This lines up with what we’re seeing in\ngenetic studies too.",
        "start": 591.68,
        "duration": 2.86
    },
    {
        "text": "Large genetic studies have identified several\ngenes that are related to",
        "start": 594.54,
        "duration": 3.08
    },
    {
        "text": "an increased risk of developing Alzheimer’s,",
        "start": 597.62,
        "duration": 2.63
    },
    {
        "text": "as well as regulate the brain’s immune response.",
        "start": 600.25,
        "duration": 2.12
    },
    {
        "text": "The jury’s still out on whether or not treating\ninflammation will be enough",
        "start": 602.37,
        "duration": 2.94
    },
    {
        "text": "to improve Alzheimer’s symptoms.",
        "start": 605.31,
        "duration": 1.67
    },
    {
        "text": "So far, clinical trials of drugs designed\nto do that haven’t been successful.",
        "start": 606.98,
        "duration": 3.859
    },
    {
        "text": "But while we continue to figure out the cause\nof Alzheimer’s,",
        "start": 610.839,
        "duration": 2.791
    },
    {
        "text": "there are some slightly more futuristic treatment\noptions on the horizon too.",
        "start": 613.63,
        "duration": 3.51
    },
    {
        "text": "As with a lot of conditions that have a genetic\ncomponent,",
        "start": 617.14,
        "duration": 2.33
    },
    {
        "text": "there’s already a lot of talk about the\npotential of gene therapies.",
        "start": 619.47,
        "duration": 3.27
    },
    {
        "text": "One example is a CRISPR-based approach, which\nis being trialed to target",
        "start": 622.74,
        "duration": 3.159
    },
    {
        "text": "the genes that snip APP to weird lengths right\nthere inside the brain,",
        "start": 625.899,
        "duration": 4.141
    },
    {
        "text": "though right now, it’s only been done in\ncell culture.",
        "start": 630.04,
        "duration": 2.07
    },
    {
        "text": "And an approach involving injecting restorative\ngenes into the brain",
        "start": 632.11,
        "duration": 2.91
    },
    {
        "text": "was reported to have begun in-human clinical\ntrials in 2021.",
        "start": 635.02,
        "duration": 3.629
    },
    {
        "text": "These genes produce brain-derived neurotrophic\nfactor, or BDNF, which is a",
        "start": 638.649,
        "duration": 4.901
    },
    {
        "text": "protein that supports the survival and growth\nof new neurons and synapses.",
        "start": 643.55,
        "duration": 4.13
    },
    {
        "text": "In those with Alzheimer’s, levels of BDNF\nare diminished, and researchers hope",
        "start": 647.68,
        "duration": 4.01
    },
    {
        "text": "that increasing the amount of this protein\nwill help keep symptoms at bay.",
        "start": 651.69,
        "duration": 3.61
    },
    {
        "text": "While we await the outcome of aducanumab’s\nphase four trial,",
        "start": 655.3,
        "duration": 3.12
    },
    {
        "text": "there’s a lot more research still moving\nforwards.",
        "start": 658.42,
        "duration": 2.22
    },
    {
        "text": "If aducanumab fails, and fears based on previous\ndata play out,",
        "start": 660.64,
        "duration": 4.11
    },
    {
        "text": "we are likely to see a lot of disappointment\nfrom patients and their families.",
        "start": 664.75,
        "duration": 3.57
    },
    {
        "text": "On a human level, that’s deeply understandable.",
        "start": 668.32,
        "duration": 2.53
    },
    {
        "text": "From a purely scientific point of view, we\nwant to update old hypotheses",
        "start": 670.85,
        "duration": 3.53
    },
    {
        "text": "with new data, and discard them if they don’t\nfit the facts.",
        "start": 674.38,
        "duration": 3.01
    },
    {
        "text": "And ethically speaking, we don’t want to\ngive people something that doesn’t work,",
        "start": 677.39,
        "duration": 3.17
    },
    {
        "text": "or creates false hope.",
        "start": 680.56,
        "duration": 1.39
    },
    {
        "text": "But being so close to what we once thought\nwould be a cure,",
        "start": 681.95,
        "duration": 3.55
    },
    {
        "text": "it can be hard to let that hope go.",
        "start": 685.5,
        "duration": 1.83
    },
    {
        "text": "Still, while it could fizzle into nothing,\nwe’re far from out of options to pursue.",
        "start": 687.33,
        "duration": 4.84
    },
    {
        "text": "Because science never really ends, it just\nchanges direction.",
        "start": 692.17,
        "duration": 3.87
    },
    {
        "text": "Thank you for watching this episode of SciShow.",
        "start": 696.04,
        "duration": 1.45
    },
    {
        "text": "I know that a lot of students and teachers\nwelcome SciShow",
        "start": 697.49,
        "duration": 2.53
    },
    {
        "text": "into your classrooms and homes.",
        "start": 700.02,
        "duration": 1.68
    },
    {
        "text": "So we’re proud to have today’s video sponsored\nby Linode, a cloud computing",
        "start": 701.7,
        "duration": 3.639
    },
    {
        "text": "company that provides easy access to teaching\ntools like Moodle",
        "start": 705.339,
        "duration": 3.611
    },
    {
        "text": "to make online learning and instructing more\nmanageable.",
        "start": 708.95,
        "duration": 2.82
    },
    {
        "text": "On Moodle, you can make quizzes, collaborative\nprojects,",
        "start": 711.77,
        "duration": 2.85
    },
    {
        "text": "and checklists to help stay on track and keep\nclasswork engaging.",
        "start": 714.62,
        "duration": 3.18
    },
    {
        "text": "While grades aren’t quite as much fun,",
        "start": 717.8,
        "duration": 1.93
    },
    {
        "text": "it’s important to have a secure place to\nkeep track of them.",
        "start": 719.73,
        "duration": 2.73
    },
    {
        "text": "Linode knows how to keep online data secure\nand has earned the trust of Moodle users.",
        "start": 722.46,
        "duration": 4.34
    },
    {
        "text": "That’s over 200,000 students and educators\naround the world.",
        "start": 726.8,
        "duration": 3.789
    },
    {
        "text": "So you can click the link in the description\nor head to linode.com/scishow",
        "start": 730.589,
        "duration": 3.87
    },
    {
        "text": "to check out Linode’s learning solutions.",
        "start": 734.459,
        "duration": 1.651
    },
    {
        "text": "That link gives you a $100 60-day credit on\na new Linode account.",
        "start": 736.11,
        "duration": 4.38
    },
    {
        "text": "Thanks to Linode for sponsoring this video.",
        "start": 740.49,
        "duration": 2.191
    },
    {
        "text": "[♪ OUTRO]",
        "start": 742.681,
        "duration": 10.321
    }
]